Ikris Pharma Network Launches Digital Platform for Named Patient Program

Ikris Pharma Network Launches Digital Platform for Named Patient Program

Named Patient Program brings medicine requests, regulatory documentation, and shipment tracking into a single platform for healthcare professionals and eligible patients to simplify global access to specialty medicines

NOIDA, India — September 9, 2026 — Ikris Pharma Network today announced the launch of Named Patient Program, a digital platform designed to simplify regulatory-compliant access to specialty medicines that are approved in other regulated markets but not yet locally available. The platform is built to help healthcare professionals and eligible patients navigate the Named Patient Import process more efficiently, bringing documentation, order tracking, and communication into one secure interface.

Many innovative therapies already approved and in use in regulated international markets remain inaccessible in other countries due to regulatory timelines, supply limitations, or market access barriers. For patients facing cancer, rare diseases, genetic disorders, and other complex or life-threatening conditions, this delay can materially affect treatment outcomes. 

What the Platform Offers:

Named Patient Program is designed around the needs of healthcare professionals and patients navigating time-sensitive treatment decisions. Core capabilities include:

  • Secure prescription and KYC document submission
  • Digital medicine request management
  • Real-time order and shipment tracking
  • Request and approval status updates
  • Regulatory-compliant import support and documentation assistance
  • EU-GMP-compliant sourcing through qualified international supply partners
  • Temperature-controlled pharmaceutical logistics

Rather than replacing existing regulatory processes, the platform is designed to improve visibility and reduce coordination friction across the medicine access journey — from initial request through delivery.

Addressing a Growing Need:

Demand for compliant access to globally approved therapies spans oncology, hematology, rare diseases, neurology, immunology, transplant medicine, genetic disorders, and specialty biologics. As precision medicine advances, hospitals and physicians increasingly need efficient pathways to therapies not yet commercially available in their market.

“Access to innovative medicines should be supported by transparency, regulatory compliance, and efficient coordination,” said Bharat Sikri, Director of Ikris Pharma Network. “Through the Named Patient Program, we aim to simplify the Named Patient Import experience for healthcare professionals and eligible patients — from medicine request and regulatory documentation to shipment tracking and delivery — connecting patients with globally approved specialty medicines when timely treatment matters most.”

Availability:

Healthcare professionals, hospitals, and eligible patients can learn more and access the platform.

Contact: https://namedpatientprogram.com/contact-us

About Ikris Pharma Network

Ikris Pharma Network is one of India’s leading Named Patient Medicine Supply companies. The company developed the Named Patient Program, a digital platform built to simplify regulatory-compliant access to globally approved but locally unavailable medicines. Ikris supports patients, physicians, and hospitals through expertise in oncology, rare disease therapies, hematology, transplant medicine, biologics, orphan drugs, regulatory documentation, GDP-compliant logistics, and international pharmaceutical sourcing.

Ikris Pharma Network Announces the Availability of Triokris™ (Trientine Dihydrochloride) to Support Patients Living With Wilson’s Disease

Ikris Pharma Network Announces the Availability of Triokris™ (Trientine Dihydrochloride) to Support Patients Living With Wilson’s Disease

Noida, India — 15 January, 2026 – Ikris Pharma Network announced the availability of Triokris™ (Trientine Dihydrochloride 250 mg Capsules), a therapeutic option for patients diagnosed with Wilson’s Disease, a rare inherited disorder of copper metabolism. Triokris is designed to support clinicians in the management of patients requiring chelation therapy, especially in cases where first-line agents are contraindicated or not tolerated.

Wilson’s Disease is a progressive condition that, if untreated, can lead to severe hepatic, neurological, and psychiatric complications due to toxic copper accumulation. Early diagnosis and long-term treatment are critical for achieving meaningful clinical outcomes.

Triokris (Trientine Dihydrochloride) is recognized internationally as a well-established chelating agent with a long-standing clinical history. It is widely used across the United States, Europe, India, and multiple global regions for the management of Wilson’s Disease. The formulation is known for its stability profile and predictable absorption characteristics.

Intended Audience Notice: This announcement is intended for healthcare professionals, hospitals, and authorized importers involved in the treatment and management of Wilson’s disease.

Key Highlights:

  • Triokris™ (Trientine Dihydrochloride 250 mg) is now available via Named Patient import pathways
  • Supports patients with Wilson’s disease who are intolerant to first-line therapy
  • Supplied under full regulatory compliance with complete quality documentation
  • Backed by GDP-aligned global logistics and pharmacovigilance oversight

Commitment to Rare Disease Care

Addressing the importance of patient access, Mr. Praveen Sikri, Founder & CEO, and Mr. Bharat Sikri, Director of Ikris Pharma Network, stated:

“Our focus has always been on supporting physicians and hospitals managing complex and rare conditions. With Triokris, we are helping enable access to a globally trusted chelation therapy for patients living with Wilson’s Disease, through compliant and well-structured pathways.”

Through its global sourcing network and regulatory-compliant import pathways, Ikris Pharma Network facilitates access to essential therapies in alignment with the Drugs & Cosmetics Act, ensuring product authenticity, full documentation, and cold-chain integrity where required.

About Triokris™ (Trientine Dihydrochloride)

Triokris is an oral chelating agent used for the removal of excess copper from the body. It is typically considered in:

  • Patients with intolerance to D-Penicillamine
  • Patients requiring maintenance therapy
  • Clinical scenarios where a stable, predictable chelator is preferred

The formulation consists of 250 mg of Trientine Dihydrochloride, developed to meet internationally accepted quality standards. Triokris is not intended to replace the clinical judgment of healthcare professionals, and treatment decisions should always be guided by a physician experienced in managing Wilson’s Disease.

Strengthening Access Through Regulatory Compliance

Ikris Pharma Network operates under strict adherence to Indian regulatory frameworks, ensuring that medicines supplied under the Named Patient Import Program follow mandated approval processes, documentation, batch traceability, and patient safety safeguards.

The organization collaborates with global manufacturers and GDP-compliant logistics partners to maintain integrity from dispatch to delivery. Each supply is backed by relevant quality documents.

A Step Forward for the Wilson’s Disease Community

The introduction of Triokris underscores Ikris Pharma Network’s mission to improve treatment access for underserved patient populations. The company continues to work closely with hepatologists, neurologists, rare disease centers, and patient support groups to strengthen awareness and early management of Wilson’s Disease.

About Ikris Pharma Network

Ikris Pharma Network is a global pharmaceutical services organization specializing in Named Patient Access, Rare Disease Medicines, Generic Medicine Export, RLD/Comparator Drug Supply, and Clinical Trial Support. The company partners with hospitals, physicians, and leading pharmaceutical manufacturers across the world to enable compliant access to hard-to-find therapies worldwide.

The company operates from its global headquarters in India and has established offices in Belgium, Bulgaria, and Hong Kong, supported by two strategic pharmaceutical warehouses in Europe. Ikris ensures end-to-end regulatory compliance, GDP-aligned supply-chain operations, and robust pharmacovigilance practices across all markets it serves.

Safety Reporting Information:

For any suspected adverse events or side effects associated with the use of Triokris™, healthcare professionals and patients are encouraged to report them by contacting drugsafety@ikrispharmanetwork.com.

Reporting safety information supports ongoing pharmacovigilance activities and helps ensure the continued safe and appropriate use of the medicine.

Disclaimer:

This material is provided for informational purposes only. Triokris™ is supplied in accordance with applicable regulatory requirements. Treatment decisions must be made by qualified healthcare professionals based on individual patient needs.

Media Contact:

Ikris Pharma Network Pvt. Ltd.
Email: info@ikrispharmanetwork.com
Website: www.ikrispharmanetwork.com
TOLL-FREE: 1800 1200 365